CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced the appointment of Jacqualyn (“Jackie”) Fouse, Ph.D., to its Board of Directors, bringing decades of leadership ...

Madrigal Pharmaceuticals, Inc. announced the appointment of Jacqualyn Fouse, Ph.D. to its Board of Directors, replacing Fred Craves, Ph.D., who will retire in July 2025. Julian Baker, Chairman of ...

In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against other best ...

March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth ...

Madrigal Pharmaceuticals has a fifty-two week low of $189.00 and a fifty-two week high of $377.46. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98.

Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $443 from $427 and keeps an Outperform rating on the shares. New 2-year data in cirrhotic patients showing a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...